Tesamorelin + Ipamorelin (FDA-Backed GHRH Analog + Selective Ghrelin-Mimetic)

Tesamorelin + ipamorelin applies the well-established GHRH-analog plus ghrelin-mimetic synergy to a pairing where the GHRH leg carries current FDA approval. Tesamorelin is the only GHRH analog in the class with an active US approval — specifically for HIV-associated visceral adiposity, where Phase III data demonstrated meaningful visceral fat reduction, improved lipid profile, and adjunct body composition benefit. Ipamorelin is the most selective ghrelin receptor agonist available, producing clean GH release without the cortisol, prolactin, or appetite effects that plague older GHRPs. The rationale for pairing them is identical to the CJC-1295 + ipamorelin rationale: two complementary receptor pathways on pituitary somatotrophs produce greater GH output than either alone. The differentiator is the GHRH leg itself. Where CJC-1295 is a compounded peptide with moderate human PK/PD data, tesamorelin has Phase III RCT evidence for its approved indication and a defined adverse event profile from post-marketing surveillance. For clinicians or patients who want the mechanistic synergy of the classic stack but prefer to anchor the protocol around an FDA-backed molecule, this pairing is the logical substitution.

The same complementary-pathway biology that drives the CJC-1295 + ipamorelin synergy applies here. Tesamorelin binds the GHRH receptor on pituitary somatotrophs, activating the cAMP/PKA signaling cascade that primes the cell for growth hormone secretion. Ipamorelin binds the separate ghrelin/GHS-R1a receptor on the same cells, activating the PLC/IP3/PKC cascade that triggers GH vesicle exocytosis. Fire both receptors simultaneously and the GH pulse is substantially larger than either peptide produces alone — the canonical GHRH + GHRP synergy first characterized with earlier-generation compounds. Tesamorelin's half-life (~26 minutes) is comparable to Modified GRF 1-29 (the no-DAC form of CJC-1295) — it's moderately short, requires daily subcutaneous dosing, and amplifies rather than replaces the body's pulsatile GH pattern. It does not produce the sustained non-pulsatile GH elevation that CJC-1295 with DAC does. For protocols that prioritize physiologic pulse architecture — most modern GH-optimization thinking — tesamorelin's kinetics are an advantage, not a drawback. Ipamorelin's selectivity is the reason the stack stays clean. Earlier GHRPs (GHRP-2, GHRP-6, hexarelin) triggered GH release but also spiked cortisol, prolactin, and hunger. Ipamorelin's tighter receptor profile produces the ghrelin-receptor pulse without those off-target effects, which is why it displaced older secretagogues as the default ghrelin-side partner in modern GH protocols.

Tesamorelin has the strongest clinical evidence base of any GHRH analog in current use. The pivotal Phase III trials in HIV-associated lipodystrophy demonstrated significant visceral adipose tissue reduction (~15-17% mean decrease), improved triglycerides, and favorable body composition shifts compared to placebo. Long-term post-marketing data supports the efficacy and safety profile, and the FDA approval (Egrifta, 2010; Egrifta SV, 2019) is based on rigorous outcomes evidence that no other compounded GHRH analog in this category has matched. Ipamorelin has published human pharmacodynamic data confirming dose-dependent GH release with minimal cortisol, prolactin, ACTH, or aldosterone effects — the defining study (Raun et al.) established its selectivity and supported its position as the cleanest GHRP-class peptide. The specific tesamorelin + ipamorelin combination has not been studied in a dedicated RCT, which is also true of the CJC-1295 + ipamorelin combination. The synergy rationale is extrapolated from the foundational GHRH + GHRP co-administration studies (Bowers et al.), which showed GH output roughly 3-fold greater than either peptide alone. That mechanistic basis applies to both stacks; the tesamorelin pairing is differentiated by the regulatory-trust and evidence-depth of the GHRH leg, not by separate combination-specific trials.

Typically administered together via subcutaneous injection, usually before bedtime to align the pharmacologic GH pulse with the natural nocturnal pulse during slow-wave sleep. Tesamorelin is FDA-approved at 2 mg once daily via subcutaneous injection; ipamorelin protocols typically use 200-300 mcg per injection, daily. Because tesamorelin's approved indication is narrow (HIV-associated lipodystrophy), off-label use for general GH optimization requires a clinician comfortable prescribing outside the label, and access is gated by brand pricing or compounded availability depending on pharmacy channel. Specific dosing, timing, and cycling should be determined by a qualified clinician; IGF-1, fasting glucose, and body composition monitoring apply as they do to any GH-axis intervention.